Cardiol Therapeutics (CRDL) News Today $1.21 0.00 (0.00%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Cardiol Therapeutics Inc. (NASDAQ:CRDL) Short Interest Up 12.4% in DecemberCardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totalling 1,270,000 shares, an increase of 12.4% from the November 30th total of 1,130,000 shares. Currently, 1.6% of the shares of the stock are sold short. Based on an average daily trading volume, of 483,200 shares, the days-to-cover ratio is currently 2.6 days.January 1, 2025 | marketbeat.comHC Wainwright Has Positive Outlook for CRDL FY2024 EarningsCardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Analysts at HC Wainwright upped their FY2024 EPS estimates for Cardiol Therapeutics in a research report issued to clients and investors on Wednesday, December 18th. HC Wainwright analyst V. Bernardino now anticipates that the company will pDecember 20, 2024 | marketbeat.comPRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent PericarditisDecember 19, 2024 | globenewswire.comCardiol Therapeutics (NASDAQ:CRDL) Earns "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $9.00 price objective on shares of Cardiol Therapeutics in a report on Wednesday.December 18, 2024 | marketbeat.com3 Penny Stocks Ready to Break Out in 2025Vuzix, GeoVox Labs, and Cardiol Therapeutics emerged as notable penny stocks late in 2024 for their potential to scale operations and launch new products.November 29, 2024 | marketbeat.comWhat is HC Wainwright's Forecast for CRDL FY2024 Earnings?Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Analysts at HC Wainwright upped their FY2024 earnings estimates for shares of Cardiol Therapeutics in a research note issued to investors on Wednesday, November 20th. HC Wainwright analyst V. Bernardino now forecasts that the company will eaNovember 22, 2024 | marketbeat.comEdward Nash Reaffirms Buy Rating for Cardiol Therapeutics: Positive Phase II Data and Strategic Future Trials Boost Market PotentialNovember 21, 2024 | markets.businessinsider.comFY2024 Earnings Forecast for CRDL Issued By Leede FinancialCardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Equities researchers at Leede Financial raised their FY2024 EPS estimates for Cardiol Therapeutics in a research note issued to investors on Tuesday, November 19th. Leede Financial analyst D. Loe now expects that the company will earn ($0.26November 21, 2024 | marketbeat.comRoth Capital Issues Pessimistic Forecast for CRDL EarningsCardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Roth Capital lowered their FY2024 earnings per share estimates for Cardiol Therapeutics in a research report issued on Tuesday, November 19th. Roth Capital analyst J. Wittes now forecasts that the company will post earnings per share of ($0.November 21, 2024 | marketbeat.comCardiol Therapeutics' (CRDL) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $9.00 price objective on shares of Cardiol Therapeutics in a research report on Wednesday.November 20, 2024 | marketbeat.comLeede Financial Has Negative View of CRDL FY2027 EarningsCardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Leede Financial reduced their FY2027 earnings estimates for Cardiol Therapeutics in a research note issued on Tuesday, November 19th. Leede Financial analyst D. Loe now expects that the company will earn $0.16 per share for the year, down frNovember 20, 2024 | marketbeat.comCardiol Therapeutics Reports Promising Phase II ResultsNovember 18, 2024 | markets.businessinsider.comCardiol Therapeutics reports promising Phase II results for recurrent pericarditis therapyNovember 18, 2024 | proactiveinvestors.comCardiol Therapeutics Inc. Added to PRISM Emerging Biotech IndexNovember 13, 2024 | globenewswire.comCardiol Therapeutics Inc. (NASDAQ:CRDL) Sees Large Increase in Short InterestCardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) saw a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 991,600 shares, an increase of 39.6% from the September 30th total of 710,500 shares. Based on an average trading volume of 414,900 shares, the days-to-cover ratio is presently 2.4 days. Currently, 1.5% of the shares of the company are sold short.October 30, 2024 | marketbeat.comHC Wainwright Issues Negative Outlook for CRDL EarningsCardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Analysts at HC Wainwright reduced their Q3 2024 EPS estimates for Cardiol Therapeutics in a research report issued to clients and investors on Thursday, October 24th. HC Wainwright analyst V. Bernardino now anticipates that the company willOctober 28, 2024 | marketbeat.comCardiol Therapeutics (NASDAQ:CRDL) Rating Reiterated by HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $9.00 price objective on shares of Cardiol Therapeutics in a research report on Thursday.October 24, 2024 | marketbeat.comCardiol Therapeutics’ Strategic Advancements Boost Market Potential and Revenue ProjectionsOctober 24, 2024 | markets.businessinsider.comCardiol Therapeutics (CRDL) Gets a Buy from Roth MKMOctober 24, 2024 | markets.businessinsider.comAre Medical Stocks Lagging Cardiol Therapeutics (CRDL) This Year?October 22, 2024 | msn.comCardiol Therapeutics to expand clinical program for recurrent pericarditis with MAVERIC-2 trialOctober 22, 2024 | proactiveinvestors.comWholesale inflation remained cool last month in latest sign that price pressures are slowingOctober 12, 2024 | ca.finance.yahoo.comCardiol Therapeutics raises $15.5M following over-allotment option exerciseOctober 11, 2024 | proactiveinvestors.comCardiol Therapeutics prices $13.5M public offeringOctober 9, 2024 | proactiveinvestors.comCardiol Therapeutics reaches target enrollment for Phase II acute myocarditis trialSeptember 24, 2024 | proactiveinvestors.comCardiol Therapeutics (CRDL) Upgraded to Buy: Here's WhySeptember 13, 2024 | msn.comRoth Capital Analysts Boost Earnings Estimates for Cardiol Therapeutics Inc. (NASDAQ:CRDL)Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Stock analysts at Roth Capital upped their Q3 2024 earnings per share (EPS) estimates for Cardiol Therapeutics in a note issued to investors on Tuesday, September 10th. Roth Capital analyst J. Wittes now forecasts that the company will postSeptember 13, 2024 | marketbeat.comStocks in play: Cardiol Therapeutics IncSeptember 11, 2024 | ca.finance.yahoo.comCardiol Therapeutics to unveil data from Phase 2 recurrent pericarditis studySeptember 10, 2024 | proactiveinvestors.comCardiol Therapeutics Inc. (NASDAQ:CRDL) Given Consensus Rating of "Buy" by BrokeragesShares of Cardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) have earned an average rating of "Buy" from the six brokerages that are currently covering the firm, MarketBeat.com reports. Five analysts have rated the stock with a buy recommendation and one has given a strong buy recommendatioSeptember 9, 2024 | marketbeat.comCardiol Therapeutics Inc. (NASDAQ:CRDL) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Cardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) have been assigned a consensus rating of "Buy" from the six analysts that are presently covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy raAugust 15, 2024 | marketbeat.comCardiol Therapeutics Inc. (NASDAQ:CRDL) Receives Consensus Recommendation of "Buy" from AnalystsShares of Cardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) have received a consensus recommendation of "Buy" from the seven research firms that are covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation and one has issued a stronJuly 21, 2024 | marketbeat.comQ2 2024 EPS Estimates for Cardiol Therapeutics Inc. Reduced by Roth Capital (NASDAQ:CRDL)Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Investment analysts at Roth Capital dropped their Q2 2024 earnings per share estimates for Cardiol Therapeutics in a report released on Tuesday, July 16th. Roth Capital analyst J. Wittes now expects that the company will post earnings of ($0July 18, 2024 | marketbeat.comCardiol Therapeutics Inc. (NASDAQ:CRDL) Sees Large Growth in Short InterestCardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) was the recipient of a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 776,300 shares, a growth of 107.6% from the May 31st total of 374,000 shares. Based on an average trading volume of 501,700 shares, the days-to-cover ratio is presently 1.5 days. Currently, 1.2% of the company's stock are sold short.June 28, 2024 | marketbeat.comCardiol Therapeutics (NASDAQ:CRDL) Receives New Coverage from Analysts at Roth MkmRoth Mkm assumed coverage on Cardiol Therapeutics in a research report on Wednesday. They set a "buy" rating and a $10.00 price target on the stock.June 26, 2024 | marketbeat.comShort Interest in Cardiol Therapeutics Inc. (NASDAQ:CRDL) Grows By 40.3%Cardiol Therapeutics Inc. (NASDAQ:CRDL - Get Free Report) was the recipient of a large growth in short interest in May. As of May 31st, there was short interest totalling 374,000 shares, a growth of 40.3% from the May 15th total of 266,500 shares. Currently, 0.6% of the shares of the stock are short sold. Based on an average trading volume of 360,800 shares, the short-interest ratio is presently 1.0 days.June 16, 2024 | marketbeat.comCardiol Therapeutics (NASDAQ:CRDL) Receives Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $9.00 target price on shares of Cardiol Therapeutics in a research report on Friday.June 14, 2024 | marketbeat.comCardiol Therapeutics releases Phase II data showing CardiolRx reduces pericarditis pain and inflammationJune 13, 2024 | proactiveinvestors.comCardiol Therapeutics (NASDAQ:CRDL) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $9.00 target price on shares of Cardiol Therapeutics in a report on Friday.June 7, 2024 | marketbeat.comClosing Bell: Cardiol Therapeutics Inc Purchase WT flat on Friday (CRDL-WT-A)May 22, 2024 | theglobeandmail.comCardiol Therapeutics Inc Class A (CRDL)May 22, 2024 | investing.comCRDL Stock Earnings: Cardiol Therapeutics Meets EPS for Q1 2024May 14, 2024 | investorplace.comCardiol Therapeutics surpasses 85% enrollment in ARCHER trial for acute myocarditisMay 14, 2024 | proactiveinvestors.comCardiol Therapeutics Inc. (NASDAQ:CRDL) Forecasted to Earn Q1 2024 Earnings of ($0.06) Per ShareCardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Stock analysts at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for Cardiol Therapeutics in a research report issued to clients and investors on Monday, April 22nd. HC Wainwright analyst V. Bernardino expects that theApril 24, 2024 | marketbeat.comCardiol Therapeutics (NASDAQ:CRDL) Coverage Initiated by Analysts at HC WainwrightHC Wainwright started coverage on Cardiol Therapeutics in a report on Monday. They issued a "buy" rating and a $9.00 price objective on the stock.April 22, 2024 | marketbeat.comCRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q4 2023April 2, 2024 | investorplace.comCardiol Therapeutics surpasses enrollment goals, prepares for topline resultsApril 2, 2024 | proactiveinvestors.comCardiol Therapeutics Inc. (NASDAQ:CRDL) Forecasted to Post FY2024 Earnings of ($0.31) Per ShareCardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Analysts at Leede Jones Gab boosted their FY2024 EPS estimates for Cardiol Therapeutics in a note issued to investors on Monday, March 25th. Leede Jones Gab analyst D. Loe now anticipates that the company will earn ($0.31) per share for theMarch 28, 2024 | marketbeat.comCardiol Therapeutics (CRDL) to Release Earnings on TuesdayCardiol Therapeutics (NASDAQ:CRDL) will be releasing earnings on Tuesday, March 26, Yahoo Finance reports.March 25, 2024 | marketbeat.comClosing Bell: Cardiol Therapeutics Inc Purchase WT down on Friday (CRDL-WT-A)March 16, 2024 | theglobeandmail.com Get Cardiol Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter. Email Address CRDL Media Mentions By Week CRDL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRDL News Sentiment▼1.870.72▲Average Medical News Sentiment CRDL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRDL Articles This Week▼01▲CRDL Articles Average Week Get Cardiol Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ALLO News TERN News AKBA News ABVX News CDXC News KOD News NMRA News ORGO News KALV News AURA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRDL) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiol Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
